The DOI matches its Crossref record; 97 of the 97 references it cites were found in a registry or an index.
Therapeutic Targets of KRAS in Colorectal Cancer
Open accessAbstract
Patients with metastatic colorectal cancer have a 5-year overall survival of less than 10%. Approximately 45% of patients with metastatic colorectal cancer harbor KRAS mutations. These mutations not only carry a predictive role for the absence of response to anti-EGFR therapy, but also have a negative prognostic impact on the overall survival. There is a growing unmet need for a personalized therapy approach for patients with KRAS-mutant colorectal cancer. In this article, we focus on the therapeutic strategies targeting KRAS- mutant CRC, while reviewing and elaborating on the discovery and physiology of KRAS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Other approaches under investigation to target mutant KRAS in CRC include perturbing the interaction between KRAS and the plasma membrane, and the combined inhibition of downstream pathways [122].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [122]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21654 · Cited by 16,522
Calcium's Role in Mechanotransduction during Muscle Development
Benavides Damm, T., & Egli, M. (2014) · Cellular Physiology and Biochemistry · doi:10.1159/000356667 · Cited by 14,502
Regulation of microRNA biogenesis
Ha, M., & Kim, V. N. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3838 · Cited by 5,462 · cited 1×
“3′ untranslated region (UTR) of a target gene leading to either degradation of mRNA or inhibition of translation [82].”
BackgroundSeger, R., & Krebs, E. G. (1995) · The FASEB Journal · doi:10.1096/fasebj.9.9.7601337 · Cited by 3,602 · cited 2×
“The RAS activates multiple downstream pathways including the RAS-RAFMEK-ERK pathway, which regulates cell cycle and proliferation [22].”
BackgroundThe role of MicroRNAs in human cancer
Peng, Y., & Croce, C. M. (2016) · Signal Transduction and Targeted Therapy · doi:10.1038/sigtrans.2015.4 · Cited by 2,483 · cited 1×
“Multiple studies have elucidated the critical role of miRNAs in cell proliferation, migration, invasion, apoptosis, and angiogenesis [83].”
BackgroundThe Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity
Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature · doi:10.1038/s41586-019-1694-1 · Cited by 2,277
Prevalence of ras gene mutations in human colorectal cancers
Bos, J. L., Fearon, E. R., Hamilton, S. R., Vries, M. V., van Boom, J. H., van der Eb, A. J., & Vogelstein, B. (1987) · Nature · doi:10.1038/327293a0 · Cited by 1,860 · cited 1×
“In Colon cancers, approximately 45% of the cases carry a KRAS mutation [11,12].”
BackgroundAll ras proteins are polyisoprenylated but only some are palmitoylated
Hancock, J. F., Magee, A. I., Childs, J. E., & Marshall, C. J. (1989) · Cell · doi:10.1016/0092-8674(89)90054-8 · Cited by 1,799 · cited 1×
“KRAS and other RAS oncogenes are intracellular guanine nucleotide-binding proteins (G proteins) that belong to the family of small GTPases and function as GDP/GTPregulated molecular switches [21].”
BackgroundKRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors
Hong, D. S., Fakih, M. G., Strickler, J. H., Desai, J., Durm, G. A., Shapiro, G. I., Falchook, G. S., Price, T. J., Sacher, A., Denlinger, C. S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1917239 · Cited by 1,733 · cited 1×
“Although the KRAS G12C is noted only in 1–3% of CRC, the recent promising clinical data breaks the assumption of KRAS being undruggable [32].”
BackgroundT-Cell Transfer Therapy Targeting Mutant KRAS in Cancer
Tran, E., Robbins, P. F., Lu, Y.-C., Prickett, T. D., Gartner, J. J., Jia, L., Pasetto, A., Zheng, Z., Ray, S., Groh, E. M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609279 · Cited by 1,368 · cited 2×
“They reported objective regression of all seven lung metastatic lesions from underlying CRC after the infusion of KRAS G12D directed TILs [95].”
Background
Research works printed but not linked: 1
- Therapeutics, M. (2021, October 28). Mirati Therapeutics Reports Investigational Adagrasib (MRTX849) Preliminary Data Demonstrating Tolerability and Durable Anti-Tumor Activity as Well as Initial MRTX1133 Preclinical Data. Available online: https://ir.mirati.com/press-releases/press-release-details/2020/Mirati-Therapeutics-Reports-Investigational-Adagrasib-MRTX849-Preliminary-Data-Demonstrating-Tolerability-and-Durable-Anti-Tumor-Activity-as-well-as-Initial-MRTX1133-Preclinical-Data/default.aspx.
Cited by
Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer
Haynes, J., & Manogaran, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051988 · Cited by 82
“Other approaches under investigation to target mutant KRAS in CRC include perturbing the interaction between KRAS and the plasma membrane, and the combined inhibition of downstream pathways [122].”
Li, C., Lau, H. C.-H., Zhang, X., & Yu, J. Q. (2022) · Biomedicines · doi:10.3390/biomedicines10071710 · Cited by 40
“Activation of KRAS is associated with various oncogenic pathways including PI3K/AKT/mTOR signaling to promote proliferation and to suppress apoptosis of tumor cells [27].”
BackgroundPostwala, H., Shah, Y., Parekh, P. S., & Chorawala, M. R. (2023) · Medical Oncology · doi:10.1007/s12032-023-02201-8 · Cited by 26
Nasioudis, D., Llauradó, M., Wong, N. K. Y., Powell, D. J., Mills, G. B., Westin, S. N., Fader, A. N., Carey, M. S., & Simpkins, F. A. (2023) · Gynecologic Oncology · doi:10.1016/j.ygyno.2023.08.007 · Cited by 18
IκBα kinase inhibitor BAY 11-7082 promotes anti-tumor effect in RAS-driven cancers
Guruvaiah, P., & Gupta, R. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05384-4 · Cited by 14
“For a long time, KRAS was considered “undruggable,” but recent studies have identified therapies targeting specific KRAS mutations, especially in treating predominantly RAS-driven cancers [4].”
Background
Metadata
- Authors
- Rahman, S., Garrel, S., Gerber, M., Maitra, R., & Goel, S.
- Affiliations
- Albert Einstein College of Medicine (US)
- Lander University (US)
- Yeshiva University (US)
- Corresponding author
- Goel, Sanjay
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2021-12-11
- Volume
- 13
- Issue
- 24
- Pages
- 6233
- ISSN
- 2072-6694 (ISSN-L)
- PMC
- PMC8699097
- OpenAlex
- W4200211768
- Cited by
- 28
- References
- 96
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 8 · 2023: 11 · 2022: 1
- FWCI
- 0.64
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cancers (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Institutes of Health (R21 AG058027 02 ( NIA))
- Yeshiva University (252869-252929, 2A4108)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- KRAS mutation, metastatic colorectal cancer, KRAS-targeted therapy, anti-EGFR therapy resistance, prognostic factors, personalized treatment, therapeutic target
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Therapeutic Targets of KRAS in Colorectal Cancer. https://app.cochat.ai/papers/10.3390/cancers13246233
- The paper
- Rahman, S., Garrel, S., Gerber, M., Maitra, R., & Goel, S. (2021). Therapeutic Targets of KRAS in Colorectal Cancer. Cancers. https://doi.org/10.3390/cancers13246233
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.